Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a transformative therapeutic approach in the management of breast cancer, particularly for patients harboring deleterious mutations in the BRCA1 and BRCA2 genes. At Alfa Cytology, we specialize in the preclinical discovery of PARP inhibitors and promotes the development of new therapies for breast cancer.
The underlying principle behind PARP inhibitor therapy lies in the concept of "synthetic lethality." PARP enzymes are responsible for the base excision repair (BER) pathway, which mends single-strand breaks in DNA. In the absence of functional BRCA1 or BRCA2 proteins, cancer cells become highly dependent on the PARP-mediated BER pathway for survival. By inhibiting PARP activity, these DNA single-strand breaks accumulate and ultimately lead to the formation of lethal double-strand breaks, triggering apoptosis selectively in the BRCA-deficient tumor cells.
Fig.1 PARP inhibitors (olaparib and talazoparib) suppress PARP catalytic activity and cause cell death in tumors with BRCA1 and BRCA2 mutations. (Demir Cetinkaya B., et al. 2022)
The remarkable efficacy and favorable safety profile of PARP inhibitors have made them a transformative addition to the breast cancer treatment landscape, particularly for patients with BRCA-mutated disease. Ongoing research aims to build upon these successes and further optimize the use of these targeted therapies.
| NCT | Targets | Therapeutics | Phase |
| NCT05582499 | PARP inhibitor + CDK inhibitor |
Fluzoparib + dalpiciclib/fluzoparib + chemotherapy | |
| NCT05332561 | PARP inhibitor | Olaparib | |
| NCT05761470 | PARP inhibitor + IO | Fluzoparib + camrelizumab + chemotherapy | |
| NCT02849496 | PARP inhibitor + IO | Olaparib + atezolizumab | |
| NCT04481113 | PARP inhibitor + CDK inhibitor |
Niraparib + abemaciclib | |
| NCT05834582 | PARP inhibitor | Fluzoparib + chemotherapy | |
| NCT03911453 | PARP inhibitor | Rucaparib | |
| NCT05498155 | PARP inhibitor + IO | Olaparib ± durvalumab | |
| NCT045842555 | PARP inhibitor + IO | Olaparib ± durvalumab |
As a leading preclinical CRO, Alfa Cytology is committed to advancing the development of innovative cancer therapies, including PARP inhibitors for breast cancer. Our state-of-the-art facilities and multidisciplinary team of experts provide comprehensive services to support the entire drug development process, from target identification and validation to preclinical studies and biomarker development.
Selective Inhibitor Development
PARP Degrader (PROTAC) Development
PARP Inhibitor Development for Breast Cancer
PARP Peptide Inhibitor Development
Dual inhibitor Development
Alfa Cytology provides development services for PARP inhibitors, covering drug design, screening, and efficacy research to find ideal drug candidates for you and accelerate preclinical research on your breast cancer therapeutics. To learn more about our capabilities in PARP inhibitor development for breast cancer or to discuss potential collaborative opportunities, please don't hesitate to contact us.
Reference